Wolverine lacks drug approval; FDA 503A pharmacy questions remain.
BPC-157 TB-500 contains ingredients without treatment approval. Here you can read the safety warnings and how pharmacy rules affect supply. Withdrawal of the pharmacy requests didn't prove safety or settle permission to supply.
Withdrawing a pharmacy request doesn't clear the safety concerns
Wolverine combines unapproved substances intended for healing. Its Wolverine legal status has changed since the 2023 notice. The applicants asked FDA to consider these ingredients for medicine mixed by pharmacies. They stopped pursuing those requests. On the FDA page current as of April 22, 2026, the entries list BPC-157 and TB-500 as withdrawn requests instead of Category 2 [13]. Category 2 is where FDA places ingredients with serious safety concerns. FDA placed BPC-157 and the Thymosin beta-4 copy called TB-500 in that group. The notice dated September 29, 2023 concerned 503A, the law covering a prescription mixed for a particular patient [13]. FDA treatment approval is missing for the mixture and its ingredients [13].
Withdrawing paperwork doesn't establish the safety of your shot.
Category 2 means FDA received enough detail to find serious risks. Category 1 covers ingredients still being considered for the permitted list. For that group, FDA temporarily holds back from enforcing certain ingredient rules against pharmacies that meet the rest of the policy's requirements [14]. This policy can let a pharmacy make medicine while review continues. The pause isn't approval, and Category 2 ingredients don't get it. The withdrawn requests still have safety warnings. The papers don't settle what a 503A pharmacy may do after withdrawal [13][14]. FDA warned that shots might trigger the immune system, which normally defends you against harm. Other concerns include unwanted material and difficulty confirming the ingredients [13]. Your questions about safety and contents are still unanswered.
The BPC-157 and TB-500 experiments on injured animals explain the interest in healing. An animal healing result settles neither human safety nor a pharmacy's permission to supply.
The July advisers discussed ingredients without approving medicines
FDA advisers discussed proposed pharmacy ingredients in July 2026. BPC-157 appeared as BPC-157 free base, the ingredient without an added acid, and BPC-157 acetate, a salt form made with acetic acid, the acid in vinegar. TB-500 appeared as TB-500 free base, also without an added acid, and TB-500 acetate, its salt form made with that same acid. These are forms of each ingredient, not separately approved medicines. Your treatment safety cannot be proved by a chemical-form name. At the July 23–24, 2026 meeting, advisers considered FDA's 503A ingredient list [15]. Their committee advises on compounding, the pharmacy practice of mixing ingredients into medicine for a patient.
Discussing an ingredient couldn't put that ingredient on the permitted list [15].
FDA staff opposed including either ingredient. By September 2026, the advisers' votes weren't published. Advisers give opinions; FDA must change the rules to change the list [14]. The July 2026 meeting gave patients no treatment approval. FDA's page dated April 22, 2026 records withdrawn requests [13]. That means the applicants stopped requesting pharmacy use. The withdrawn paperwork cannot answer your supply question, because an applicant stopping a request is different from an FDA decision permitting the ingredient in pharmacy-made medicine.
The ingredients aren't listed in Category 2, the serious-risk group, on that page. Withdrawal leaves the safety warnings standing. Pharmacy permission also remains unresolved after the July 2026 discussion. These papers don't establish whether pharmacies may now supply the ingredients. The missing answer matters even when you hold a prescription. Neither the meeting nor the withdrawn requests establishes an approved medicine.
A prescription names the patient but doesn't settle ingredient permission
United States law allows specially mixed medicines under stated conditions. Section 503A applies to licensed pharmacies and doctors, usually filling one patient's prescription. Section 503B applies to registered businesses making larger batches under FDA production rules [14]. These legal sections don't approve particular ingredients.
Before prescribing, a licensed prescriber examines the patient and considers the need. The visit may happen by screen where the law allows. The prescription names the person receiving the medicine [14]. Preparation may happen at a 503A pharmacy; supply may come from a 503B business. These routes still depend on the law's requirements. Your prescription records what a prescriber chose after assessing you, but the ingredient also has to meet the rules that govern the pharmacy [14]. A visit through a screen instead of in an office still requires the prescriber to examine the patient and write a proper prescription, while the medicine must also meet the rules that govern its ingredients.
Your prescription alone cannot prove that the ingredient is permitted.
The law gives several ways for an ingredient to qualify. One route is an entry in the official drug-standards book. Another is use within a medicine already approved by FDA. Inclusion on FDA's 503A permitted-ingredient list is another [14]. An ingredient with a serious-risk warning doesn't qualify for routine 503A mixing while that warning remains [13]. BPC-157 and TB-500 received those warnings in 2023. The current entries record withdrawn requests. The papers don't establish that either ingredient now meets one of those choices. FDA hasn't explained what withdrawal allows. You still need a supply answer separate from the prescriber's choice. A prescription doesn't supply that missing permission or prove that the medicine will help.
Sports rules bar these substances even between competitions
The drug bans in regulated sport are set by the World Anti-Doping Agency. BPC-157 is barred because it lacks approval as medicine. TB-500 and whole Thymosin Beta-4 are barred because the sports rules cover certain growth-promoting substances [7]. Athletes face these bans during competitions and between competitions [7]. Pharmacy law is a separate question for you. BPC-157 TB-500 lacks drug approval, and neither ingredient is allowed under these sports rules [7]. Permission discussions about pharmacies don't remove a sports ban.
The FDA notices don't decide the separate sports question
FDA 503A notices warned about the separate ingredients
The September 29, 2023 FDA notice assigned both ingredients to Category 2, the group with serious safety concerns. The page dated April 22, 2026 records withdrawn requests [13]. Category 2 ingredients don't get the temporary pause in certain FDA enforcement given to Category 1 ingredients [14]. The entries concern separate ingredients. No separate ruling covers the mixture [13].
BPC-157 withdrawal doesn't establish pharmacy permission
The BPC-157 entry records a withdrawn request on the page FDA dated April 22, 2026. Leaving Category 2 by withdrawal doesn't prove permission under 503A [13]. The 503A/503B laws still require a patient examination plus a proper prescription and ingredient permission [14]. You cannot infer a supply decision from withdrawal alone.
Wolverine (BPC-157 + TB-500) still has no approval for medical care
BPC-157 and TB-500 remain without FDA approval as human treatments [13]. The September 29, 2023 notice put both into 503A Category 2. Neither received the enforcement pause offered to Category 1 ingredients [13][14]. Safety warnings remain with the withdrawn requests. No published ruling settles what a pharmacy may supply afterward. Both substances are barred in regulated sport too [7].
BPC-157 and TB-500 remain barred under sports rules
Neither the separate ingredients nor the mixture has treatment approval [13]. BPC-157 is barred as unapproved by the World Anti-Doping Agency. Its growth-related rules also bar TB-500 and whole Thymosin Beta-4 [7]. Discussions of pharmacy use don't change these sports rules for you.